Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
TREACE MEDICAL CONCEPTS, INC. (TMCI)
|
Add to portfolio |
|
|
|
| Price: |
$19.95
| | Metrics |
| OS: |
61.5
|
M
| |
-34
|
% ROE
|
| Market cap: |
$1.23
|
B
| |
-29
|
% ROIC
|
|
Net cash:
|
$12
|
M
| |
$0.20
|
per share
|
|
EV:
|
$1.22
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($49.3)
|
M
| |
|
|
|
EBIT
|
($53.3)
|
M
| |
|
|
| EPS |
($0.86)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-05-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-05-20 | Dec-31-19 |
| Revenues | 141.8 | 141.8 | 94.4 | 94.4 | 57.4 | 57.4 | 39.4 |
| Revenue growth | 50.2% | 50.2% | 64.6% | 64.6% | 45.5% | | |
| Cost of goods sold | 27.5 | 27.5 | 17.8 | 17.8 | 12.5 | 12.5 | 7.6 |
| Gross profit | 114.3 | 114.3 | 76.6 | 76.6 | 44.9 | 44.9 | 31.8 |
| Gross margin | 80.6% | 80.6% | 81.1% | 81.1% | 78.3% | 78.3% | 80.6% |
| Sales and marketing | 102.6 | 102.6 | 64.5 | 64.5 | 31.7 | 31.7 | 25.8 |
| Research and development | 13.6 | 13.6 | 10.2 | 10.2 | 5.8 | 5.8 | 5.1 |
| General and administrative | 33.0 | 33.0 | 18.4 | 18.4 | 6.5 | 6.5 | 4.5 |
| EBIT | -34.8 | -34.8 | -16.5 | -16.5 | 0.9 | 0.9 | -3.5 |
| EBIT margin | -24.6% | -24.6% | -17.5% | -17.5% | 1.5% | 1.5% | -9.0% |
| Pre-tax income | -42.8 | -42.8 | -20.6 | -20.6 | -3.7 | -3.7 | -4.3 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -42.8 | 0.0 | -20.7 | 0.0 | -4.3 | 0.0 | -4.9 |
| Net margin | -30.2% | 0.0% | -22.0% | 0.0% | -7.5% | 0.0% | -12.4% |
| |
| Diluted EPS | ($0.77) | ($0.77) | ($0.43) | ($0.43) | ($0.12) | ($0.12) | ($0.13) |
| Shares outstanding (diluted) | 55.3 | 0.1 | 48.4 | 0.0 | 37.1 | 0.0 | 36.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|